KRAS and familial pancreatic carcinoma: For example, patient PANC-0117 had stage I pancreatic cancer at the time of surgery, with two pathogenic mutations present in the tumor (KRAS G12D and TP53 P152L) that were not detectable in the plasma sample (Table 2).